TRENDS IN INFECTIONS IN CHILDREN WITH MALIGNANT DISEASE IN 2000: Comparison of Data of 1980/81

Children with cancer have an overall chance of survival of 70–80%. Despite significant advances in supportive care during the last years, infections remain a major cause of therapy-associated morbidity and death. Between January and December 2000, oncology patients (ONC) treated on a pediatric oncology ward after chemotherapy (n = 109), loco-regional thermochemotherapy (n = 13), or hematopoetic stem cell (HSCT) transplantation (n = 35) suffered a total of 249 febrile infectious complications (HSCT 40/ONC 209). These episodes were analyzed retrospectively and compared with 125 ONC patients with 133 febrile infections in 1980/81. The relative incidence of fever of unknown origin (FUO) decreased from 1980/81 to 2000 (p <.001). The frequency of bloodstream infections (BSI) in febrile episodes was comparable in both periods with 37% (50/135) in 1980 and 29% (72/249) in 2000. In both periods, gram-positive bacteria were the most frequent organisms, whereas gram-negative organisms were detected in approximately 20% of BSI. In 1980/81 microbiologically (MDI) or clinically documented infections (CDI) were not detected, whereas in 2000 27% of all infectious were MDI/CDI. During the last 20 years, improved diagnostic tools have resulted in an increased detection rate of infectious agents causing febrile episodes in pediatric cancer patients. The comparison of the two observation periods did not reveal a change in the microbiologic spectrum. Despite the fact that in 2000 more patients were treated with intensified chemotherapy because of relapse, infection-related mortality was unchanged compared to 1980/81. This observation may indicate a sufficient preemptive antibacterial therapy followed by better diagnostic tools and goal-oriented treatment.

[1]  M. Blettner,et al.  [Follow up of long-term survivors after childhood cancer in Germany]. , 2005, Klinische Padiatrie.

[2]  J. Zunt,et al.  Parasitic central nervous system infections in immunocompromised hosts. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  I. Haznedaroglu,et al.  Cytarabine-induced fever complicating the clinical course of leukemia , 2005, Anti-cancer drugs.

[4]  F. Bonetti,et al.  Prophylactic co-trimoxazole versus norfloxacin in neutropenic children — perspective randomized study , 1989, Infection.

[5]  F. Watzinger,et al.  Real-Time Quantitative PCR Assays for Detection andMonitoring of Pathogenic Human Viruses in ImmunosuppressedPediatricPatients , 2004, Journal of Clinical Microbiology.

[6]  D. Reinhardt,et al.  Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93 , 2004, Leukemia.

[7]  R. Willers,et al.  An Approach for Cure: PEI-Chemotherapy and Regional Deep Hyperthermia in Children and Adolescents with Unresectable Malignant Tumors , 2003, Klinische Padiatrie.

[8]  C. Kramm,et al.  Pre-eruptive varicella zoster virus encephalitis in two children after haematopoietic stem cell transplantation. , 2002, Medical and pediatric oncology.

[9]  C. Viscoli,et al.  Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG). , 2002, European journal of cancer.

[10]  K. Roemer,et al.  Evaluation of Use of Epstein-Barr Viral Load in Patients after Allogeneic Stem Cell Transplantation To Diagnose and Monitor Posttransplant Lymphoproliferative Disease , 2002, Journal of Clinical Microbiology.

[11]  J. Michálek,et al.  High incidence of Epstein-Barr virus, cytomegalovirus and human herpesvirus 6 infections in children with cancer , 2002, BMC pediatrics.

[12]  C. Kramm,et al.  Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma – a rationale for tailored supportive care , 2001, Supportive Care in Cancer.

[13]  J. Shenep,et al.  Aspergillosis in children with cancer: A 34-year experience. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Šufliarský,et al.  Nosocomial candidaemias due to species other than Candida albicans in cancer patients , 1999, Supportive Care in Cancer.

[15]  A. Groll,et al.  Five‐year‐survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long‐term survival , 1999, Mycoses.

[16]  D. Denning,et al.  Invasive yeast infections other than Candida spp. in acute leukaemia. , 1999, The Journal of hospital infection.

[17]  M. Andrew,et al.  Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  C. Chenoweth,et al.  Risk factors for candidemia in a children's hospital. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  M. Cheang,et al.  Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  C. Viscoli Aspects of infections in children with cancer. , 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[21]  J. Klastersky Empirical antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. , 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[22]  S. Feldman,et al.  Varicella in children with cancer: impact of antiviral therapy and prophylaxis. , 1987, Pediatrics.

[23]  H. Jürgens,et al.  Microbial spectrum of blood and body cultures in febrile episodes of children under chemotherapy for treatment of malignant diseases. , 1987, Pediatric hematology and oncology.

[24]  U. Göbel,et al.  Die kooperative Ewing-Sarkom-Studie CESS 81 der GPO - Analyse nach 4 Jahren* +( * , 1985 .

[25]  P. Voûte,et al.  [The Cooperative Ewing Sarcoma Study CESS 81 of the German Pediatric Oncology Society--analysis after 4 years]. , 1985, Klinische Padiatrie.

[26]  W. Johnson,et al.  Fatalities during remission of childhood leukemia. , 1972, Blood.